Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia
Por um escritor misterioso
Descrição
October 1st sees the PBS listing of REXULTI, a novel antipsychotic indicated for the treatment of adults with schizophrenia.
Full article: In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole
Michael Okun on X: Brexpiprazole (Rexulti) approved by FDA for #Alzheimers agitation. Will it find its way to #Parkinsons? Depends on if it makes motor symptoms significantly worse. It works on D2
Full article: Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human
Investigation Questions Drug's Approval for Agitation in AD
Brexpiprazole - Prescriber's Guide
Rexulti (Brexpiprazole) for the Treatment of Major Depressive Disorder (MDD) and Schizophrenia - Clinical Trials Arena
The Visual Illusion of Efficacy in Psychiatric Drug Trials - Mad In America
Brexpiprazole - Mechanism of Action and Clinical Application
Full article: Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human
ex9902003.jpg
ex9901_img005.jpg
Dichlorophenyl piperazines, including a recently-approved atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol biosynthesis. - Abstract - Europe PMC
ex9901_img001.jpg
The Best and Worst Antipsychotics for Mania - Part 2, 2021-10-25
de
por adulto (o preço varia de acordo com o tamanho do grupo)
